IP Library Granted Patent US 12,251,373
Granted Patent B2
US 12,251,373 · App. 18/461,023 · Granted Mar 18, 2025

Compounds and methods of treating retinal degeneration

Inventors: Krzysztof Palczewski (Ivrine, CA); Yuanyuan Chen (Pittsburgh, PA)
Assignees: CASE WESTERN RESERVE UNIVERSITY; UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
A61K31/4402A61K31/365A61K31/381A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,373
App. No.
18/461,023
Granted
Mar 18, 2025
Kind
B2
Abstract

A method of treating retinal degeneration in a subject includes administering to the subject a therapeutically effective amount of a compound of formula (I).

Claims (16)

1. A compound having formula (I);

wherein X 1 is CH 2 , C═O, or N—R 3 ;

wherein X 2 is O or N—R 4 ;

wherein at least one of X 1 is not N—R 3 or X 2 is not N—R 4 ;

wherein R 1 and R 2 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein at least one of R 1 or R 2 is a substituted or unsubstituted thiophene;

wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S), C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, —Si(C 1 -C 3 alkyl) 3 , hydroxyl, sulfhydryl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C 2 -C 24 alkylcarbonato, C 6 -C 20 arylcarbonato, carboxy, carboxylato, carbamoyl, C 1 -C 24 alkyl-carbamoyl, arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, isothiocyanato, azido, formyl, thioformyl, amino, C 1 -C 24 alkyl amino, C 5 -C 20 aryl amino, C 2 -C 24 alkylamido, C 6 -C 20 arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C 1 -C 24 alkylsulfanyl, arylsulfanyl, C 1 -C 24 alkylsulfinyl, C 5 -C 20 arylsulfinyl, C 1 -C 24 alkylsulfonyl, C 5 -C 20 arylsulfonyl, phosphono, phosphonato, phosphinato, phospho, or phosphino or combinations thereof;

and pharmaceutically acceptable salts thereof.

2. A compound having formula (III):

wherein R 2 and R 6 are each individually hydrogen, a substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S), C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, —Si(C 1 -C 3 alkyl) 3 , hydroxyl, sulfhydryl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C 2 -C 24 alkylcarbonato, C 6 -C 20 arylcarbonato, carboxy, carboxylato, carbamoyl, C 1 -C 24 alkyl-carbamoyl, arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, isothiocyanato, azido, formyl, thioformyl, amino, C 1 -C 24 alkyl amino, C 5 -C 20 aryl amino, C 2 -C 24 alkylamido, C 6 -C 20 arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C 1 -C 24 alkylsulfanyl, arylsulfanyl, C 1 -C 24 alkylsulfinyl, C 5 -C 20 arylsulfinyl, C 1 -C 24 alkylsulfonyl, C 5 -C 20 arylsulfonyl, phosphono, phosphonato, phosphinato, phospho, or phosphino or combinations thereof;

and pharmaceutically acceptable salts thereof.

3. A compound having formula (IV):

wherein R 1 and R 7 are each individually hydrogen, a substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S), C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, —Si(C 1 -C 3 alkyl) 3 , hydroxyl, sulfhydryl, C 1 -C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C 2 -C 24 alkylcarbonato, C 6 -C 20 arylcarbonato, carboxy, carboxylato, carbamoyl, C 1 -C 24 alkyl-carbamoyl, arylcarbamoyl, thiocarbamoyl, carbamido, cyano, isocyano, cyanato, isocyanato, isothiocyanato, azido, formyl, thioformyl, amino, C 1 -C 24 alkyl amino, C 5 -C 20 aryl amino, C 2 -C 24 alkylamido, C 6 -C 20 arylamido, imino, alkylimino, arylimino, nitro, nitroso, sulfo, sulfonato, C 1 -C 24 alkylsulfanyl, arylsulfanyl, C 1 -C 24 alkylsulfinyl, C 5 -C 20 arylsulfinyl, C 1 -C 24 alkylsulfonyl, C 5 -C 20 arylsulfonyl, phosphono, phosphonato, phosphinato, phospho, or phosphino or combinations thereof;

and pharmaceutically acceptable salts thereof.

4. The compound of claim 1 , wherein R 3 and R 4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted C 1 -C 24 alkyl, a substituted or unsubstituted cycloalkyl, heterocyclyl, aryl, and heteroaryl.

5. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

Continuity (5)
Continuation 17544454 · Dec 7, 2021
Continuation 16609162
Provisional Application 62645576 · Mar 20, 2018
Provisional Application 62491811 · Apr 28, 2017
Related Publication 20240041847A1 · Feb 8, 2024
References Cited (11)
US 1191752A · Walsh et al. · 1916 [cited by examiner]
US 7012094B1 · Bertenshaw et al. · 2006 [cited by applicant]
US 11191752B2 · Palczewski · 2021 [cited by examiner]
US 11744826B2 · Palczewski · 2023 [cited by examiner]
US 20020032230A1 · Pal et al. · 2002 [cited by applicant]
US 20140235562A1 · Palczewski et al. · 2014 [cited by applicant]
Behnen et al. “A Small Chaperone Improves Folding and Routing of Rhodopsin Mutants Linked to Inherited Blindness,” iScience, Jun. 29, 2018 (Jun. 29, 2018), vol. 4, pp. 1-19. [cited by applicant]
Chen et al. “A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration,” Nature Communications, May 17, 2018 (May 17, 2018), vol. 9, No. 1976, pp. 1-18. [cited by applicant]
Chen et al. “Transcriptome Profiling of NIH3T3 Cell Lines Expressing Opsin and the P23H Opsin Mutant Identifies Candidate Drugs for the Treatment of Retinitis Pigmentosa,” Pharmacol Res, Nov. 9, 2016 (Nov. 9, 2016), vol… [cited by applicant]
Herrera-Hernandez et al. “Flavonoid allosteric modulation of mutated visual rhodopsin associated with retinitis pigmentosa,” Scientific Reports, Sep. 11, 2017 (Sep. 11, 2017), vol. 7, No. 11167, pp. 1-13. [cited by applicant]
Noorwez et al. “Pharmacological Chaperone-mediated in Vivo Folding and Stabilization of the P23H-opsin Mutant Associated with Autosomal Dominant Retinitis Pigmentosa,” The Journal of Biological Chemistry, Apr. 18, 2003 … [cited by applicant]